

IN THE CLAIMS:

1. (Cancel) ~~Topical treatment of psoriasis with formulations (creams, gels, . . .) to accomplish non-physiologic high concentrations of Epidermal Growth Factor (EGF), which can down-regulate the expression of the EGF-Receptor.~~
2. (Cancel) ~~Psoriasis treatment with topical formulations, containing EGF in concentrations of 0.01 to to 50 micrograms/gram.~~
3. (Cancel) ~~Topical formulations containing 0.5-20 microgram EGF/gram of formulation.~~
4. (Cancel) ~~Topical creams, containing 0.1-3% sulfadiazine and 0.5-20 micrograms EGF/gram for the treatment of psoriasis.~~
5. (Cancel) ~~Topical formulations, containing anti-inflammatory products, in combination with epidermal growth factor.~~
6. (Cancel) ~~Topical formulations, containing EGF in combination with anti-inflammatory products and other dermatologically beneficial products, for the treatment of proriasis.~~
7. (Cancel) ~~Topical formulations, containing 10µg EGF and 1% of sulfadiazine for the treatment of psoriasis.~~
8. (Cancel) ~~Systemic treatment of psoriasis patients with 0.001-10 microgram of EFG/kg.~~
9. (Original) Topical and systemic treatment of psoriasis patients with precursor molecules of epidermal growth factor, such as fibroblast growth factor.

10. (Original) Treatment with products, with similar biological action as EGF, such as urogastrone or fractions of the EGF molecule.

11. (New) A method for treating psoriasis in a patient in need thereof comprising the step of administering a topical formulation,

wherein said formulation comprises epidermal growth factor as the sole active agent, and wherein the patient is a human being.

12. (New) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.01 to 50 micrograms/gram formulation.

13. (New) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.5 to 20 micrograms EGF/gram formulation.

14. (New) The method according to claim 11, wherein the formulation further comprises an anti-inflammatory product.

15. (New) The method according to claim 14, wherein the formulation is a topical cream containing 0.1 to 3% (w/w) of sulfadiazine and 0.5 to 20 micrograms EGF/gram formulation.

16. (New) The method according to claim 14, wherein the formulation comprises 10µg EGF and 1% (w/w) sulfadiazine.

17. (New) A method for treating psoriasis in a patient in need thereof comprising the step of systemically administering 0.001 to 10 micrograms of EGF/kg body weight.